Surasak Puvabanditsin, MD

Ongoing projects:

• Inhaled Nitric Oxide For The Prevention Of Bronchopulmonary Dysplasia (BPD) In Preterm Infants Requiring Mechanical Ventilation Or Positive Pressure Support On Days 5-14 After Birth (IK-3001-BPD-301

Future projects:

• Randomizes, Double-Blind, Multi-Center Study to Compare the efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis

Principal Investigator

1) Principal Investigator Clinical Protocol No. SHP607-202 “A Phase 2b/3, Multicenter, Randomized, Open- label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age (CA) Compared to Standard Neonatal Care in Extremely  Premature Infants”   
July 2019 – December 2022   

2) Principal Investigator Clinical Protocol No.C3591025: A phase 2a, 2-part, open-label, non-randomized,    
multicenter, single and multiple dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in neonates and infants from birth to less than 3 months of age with suspected or confirmed infection due to gram-negative pathogens requiring intravenous antibiotic treatment 
May 2020- December 2021

3) Principal Investigator Clinical Protocol No. MK-1654-004: A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants 
December 2021-2025

4) Principal Investigator Clinical Protocol No. MK1654-007: A Phase 3, Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease 
August 2022- December 2025

5) Principal Investigator Clinical Protocol No.  C3601010: A Phase 2a, 2-part, Open-Label, Non-randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam ± Metronidazole in Neonates and Infants From Birth to Less Than 9 Months of Age with Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment 
July 2024 – December 2026

Undergraduate Education:
Mahidol University
Degree: B.Sc. 
Date: 4/1975

Graduate Education:
Ramathibodi Faculty of Medicine at Mahidol University
Bangkok, Thailand
Degree: M.D. 
Date:     4/1977

POSTGRADUATE TRAINING:
         
Fellow in Neonatology
Division of Neonatology
UMDNJ Newark, NJ

Undergraduate Education:
Mahidol University  
Degree: B.Sc. 
Date: 4/1975

Graduate Education:

Ramathibodi Faculty of Medicine at Mahidol University
Bangkok, Thailand
Degree: M.D. 
Date:     4/1977

POSTGRADUATE TRAINING:      

Fellow in Neonatology Division of Neonatology
UMDNJ Newark, NJ
6/1983 - 7/1985

Resident in Pediatrics
Jewish Hospital of Brooklyn
Brooklyn, NY
6/80-7/83  

Public Health Student
Tulane Medical Center
New Orleans, LA
9/1979 - 5/1980

Resident in General Practitioner
Faculty of Medicine, Ramathibodi Hospital
Bangkok, THAILAND
4/1978 - 4/1979

 Internship
Faculty of Medicine, Ramathibodi Hospital
Bangkok, THAILAND
4/1977 - 4/1978

Pediatric Attending of the Year, Jersey City Medical Center:
  1991, 1994, 1995, 1996, 1999, 2002, 2004, 2005